**11. Acid suppression with potassium-competitive acid blockers**

Vonoprazan is the first and most extensively studied potassium-competitive acid blocker (P-CAB). Vonoprazan has a rapid onset of action, longer duration of action, and more profound acid suppression compared to PPIs. It is currently undergoing phase 3 clinical trials in the USA and Europe, and so far, it has yielded promising results in both dual and triple therapy [2].

### **12. Role of probiotics in management**

Probiotics are given as an adjuvant treatment with eradication therapy as they improve eradication rates, reduce the side effects of antibiotics, and improve compliance. However, the strength of the evidence supporting their use is not strong enough because studies are either of weak quality or have a potential risk of bias. There is no strong evidence to suggest that single-strain probiotics work better than multiplestrain probiotics [1].
